Drug-Eluting Stent for Recurrent Mesenteric Artery In-Stent Restenosis

Purpose: To report the use of a drug-eluting stent (DES) for treatment of symptomatic in-stent restenosis (ISR) in the superior mesenteric artery (SMA). Case Report: A 79-year-old woman suffering from chronic renal failure and needing dialysis was admitted for vomiting, postprandial abdominal pain, and weight loss for 3 months. Computed tomographic angiography (CTA) documented massive calcification of the vascular bed, mainly in the aorta, and a very tight ostial stenosis of the SMA. A 4.5-x20-mm Genesis stent was deployed at the ostium, with good angiographic result and immediate symptomatic benefit. After 3 months, symptoms recurred; angiography demonstrated ISR. Percutaneous angioplasty with a 4-x15-mm cutting balloon was performed. The patient remained asymptomatic for only 2 months; recurrent ISR at this time was treated with a 3.5-x24-mm coronary TAXUS Express paclitaxel-eluting coronary stent deployed inside the previously implanted stent. Under prolonged double antiplatelet regimen, the patient was asymptomatic at the 8-month follow-up; CTA demonstrated patency of the SMA. Conclusion: Considering the high rate of restenosis and the periprocedural complications described with endovascular treatment of SMA stenosis, a drug-eluting stent may be a good option not only for the treatment of restenosis but also in de novo lesions, at least when the vessel diameter is <4.5 mm.

Download Full-text

Possible effect of direct oral anti-coagulant for preventing long stenting lesion from in-stent restenosis in femoropopliteal segment: Case report with angioscopy findings

SAGE Open Medical Case Reports ◽

10.1177/2050313x20945535 ◽

2020 ◽

Vol 8 ◽

pp. 2050313X2094553

Author(s):

Taketsugu Tsuchiya ◽

Satori Akita ◽

Minako Oda ◽

Takaaki Takamura ◽

Katsuhide Kitagawa ◽

...

Keyword(s):

De Novo ◽

Successful Outcome ◽

Drug Eluting Stent ◽

Vein Thrombosis ◽

Stent Restenosis ◽

Balloon Catheters ◽

Nitinol Stents ◽

Drug Eluting ◽

Zilver Ptx ◽

In Stent Restenosis

A 64-year-old female underwent a successful first percutaneous intervention using MISAGO stents for a de novo femoropopliteal lesion. Subsequently, three more effective procedures were done using balloon catheters for in-stent restenosis. In May 2016, a fourth procedure using Zilver PTX stent for in-stent restenosis was carried out. For this final procedure, we added direct oral anti-coagulant as she had additional problem of popliteal vein thrombosis and her femoropopliteal segment remained clear. A Zilver PTX stent, a drug-eluting stent for a peripheral artery, was expected to bring superior outcomes compared to conventional bare nitinol stents (i.e. MISAGO stent). But subsequent studies reported that Zilver PTX stent was not more effective than conventional bare nitinol stents. In our above mentioned case, her angioscopy findings suggest that her successful outcome appears to be related to the added direct oral anti-coagulant.

Download Full-text

Drug-Eluting Stent for Recurrent Mesenteric Artery In-Stent Restenosis

Journal of Endovascular Therapy ◽

10.1583/1545-1550(2007)14[748:dsfrma]2.0.co;2 ◽

2007 ◽

Vol 14 (5) ◽

pp. 748-751 ◽

Cited By ~ 1

Author(s):

Paolo Cardaioli ◽

Gianluca Rigatelli ◽

Luca Zattoni ◽

Massimo Giordan

Keyword(s):

Mesenteric Artery ◽

Drug Eluting Stent ◽

Stent Restenosis ◽

Drug Eluting ◽

In Stent Restenosis

Download Full-text

Long-Term Outcomes of Drug-Eluting Stent Therapy for In-Stent Restenosis Versus De Novo Lesions

Journal of Interventional Cardiology ◽

10.1111/joic.12069 ◽

2013 ◽

Vol 26 (6) ◽

pp. 550-555 ◽

Cited By ~ 1

Author(s):

ZHAN GAO ◽

BO XU ◽

YUE-JIN YANG ◽

JIN-QING YUAN ◽

JUE CHEN ◽

...

Keyword(s):

De Novo ◽

Drug Eluting Stent ◽

Long Term Outcomes ◽

Stent Restenosis ◽

Drug Eluting ◽

In Stent Restenosis

Download Full-text

TCTAP A-030 Drug Coated Balloon Versus Drug-eluting Stent for In-stent Restenosis After Drug-eluting Stent Implantation: A Meta-analysis

Journal of the American College of Cardiology ◽

10.1016/j.jacc.2021.03.056 ◽

2021 ◽

Vol 77 (14) ◽

pp. S19

Author(s):

Hendy Bhaskara Perdana Putra ◽

Quri Meihaerani Savitri ◽

Wally Wahyu Mukhammad ◽

Atiyatum Billah ◽

Alan Dharmasaputra ◽

...

Keyword(s):

Stent Implantation ◽

Meta Analysis ◽

Drug Eluting Stent ◽

Stent Restenosis ◽

Drug Eluting ◽

Drug Coated Balloon ◽

In Stent Restenosis

Download Full-text

Corrigendum to “A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway” [Bioact. Mater. 6 2 (February 2021) 375–385]

Bioactive Materials ◽

10.1016/j.bioactmat.2021.07.032 ◽

2021 ◽

Author(s):

Yinping Zhao ◽

Guangchao Zang ◽

Tieying Yin ◽

Xiaoyi Ma ◽

Lifeng Zhou ◽

...

Keyword(s):

Smooth Muscle ◽

Vascular Smooth Muscle ◽

Smooth Muscle Cells ◽

Arsenic Trioxide ◽

Vascular Smooth Muscle Cells ◽

Muscle Cells ◽

Drug Eluting Stent ◽

Stent Restenosis ◽

Drug Eluting ◽

In Stent Restenosis

Download Full-text

CRT-48 Drug Eluting Balloon for De-Novo, In stent Restenosis and Bifurcation Lesions of Coronary Artery Disease: Short and Intermediate Results, Prospective Registry

JACC Cardiovascular Interventions ◽

10.1016/j.jcin.2012.12.058 ◽

2013 ◽

Vol 6 (2) ◽

pp. S16-S17

Author(s):

Saad Mohamed Al Kasab ◽

Menwar Mutared Al Anazi ◽

Ali AlMasood ◽

Mohammed AlKasab ◽

Rida Nourallah

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

De Novo ◽

Stent Restenosis ◽

Drug Eluting ◽

Bifurcation Lesions ◽

Intermediate Results ◽

Artery Disease ◽

Drug Eluting Balloon ◽

In Stent Restenosis

Download Full-text

The effect of REDV/TiO2 coating coronary stents on in-stent restenosis and re-endothelialization

Journal of Biomaterials Applications ◽

10.1177/0885328216675829 ◽

2016 ◽

Vol 31 (6) ◽

pp. 911-922 ◽

Cited By ~ 7

Author(s):

Xiangshan Xu ◽

Lijie Wang ◽

Guofeng Wang ◽

Yuanzhe Jin

Keyword(s):

Metal Ion ◽

316L Stainless Steel ◽

Ceramic Coating ◽

Bare Metal Stent ◽

Drug Eluting Stent ◽

Bare Metal ◽

Metal Stent ◽

Stent Restenosis ◽

Drug Eluting ◽

In Stent Restenosis

The coronary artery stent has been widely used in clinic. In-stent restenosis was mainly caused by the excessive proliferation of smooth muscle cell and the inflammation due to the metal ion released from stent scaffold of the drug-eluting stent. Thus, to reduce the in-stent restenosis and promote the vascular endothelialization have become a hot research point in this area. In this paper, a nano-TiO2 ceramic coating was deposited on 316L stainless steel to reduce the metal ion release and to inhibit the inflammation reaction. An endothelia cell selective adhesion peptide Arg-Glu-Asp-Val (REDV) coating was prepared on the ceramic coating by a polydopamine technology to promote the endothelialization. The corrosion test indicated that nano-TiO2 ceramic film could effectively decrease the nickel ion released from 316L stainless steel. REDV/TiO2 coating could promote the endothelial cell adhesion and proliferation, meanwhile REDV/TiO2 coating could also increase the nitric oxide concentration. Bare metal stent, TiO2-coated stent and REDV/TiO2-coated stent were implanted in the iliac arteries of rabbit model. In-stent restenosis and re-endothelialization were evaluated at 28 days post-implantation of the stents. The results showed that REDV/TiO2-coated stents could effectively reduce in-stent restenosis and promote re-endothelialization in comparison with TiO2-coated drug-eluting stent and bare metal stent. These results suggest that REDV/TiO2-coated drug-eluting stent maybe a good choice of the application for coronary artery disease.

Download Full-text